La Jolla Pharmaceutical Co. (LJPC)

32.62
0.01 0.03
NASDAQ : Health Technology
Prev Close 32.63
Open 32.62
Day Low/High 32.29 / 33.09
52 Wk Low/High 22.68 / 41.36
Volume 140.02K
Avg Volume 515.20K
Exchange NASDAQ
Shares Outstanding 26.15M
Market Cap 861.51M
EPS -5.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Interesting LJPC Put And Call Options For May 18th

Interesting LJPC Put And Call Options For May 18th

Investors in La Jolla Pharmaceutical Co. saw new options become available this week, for the May 18th expiration.

La Jolla Pharmaceutical (LJPC) Shares Cross Above 200 DMA

La Jolla Pharmaceutical (LJPC) Shares Cross Above 200 DMA

In trading on Thursday, shares of La Jolla Pharmaceutical Co. crossed above their 200 day moving average of $32.07, changing hands as high as $32.68 per share.

GIAPREZA™ (angiotensin II) Significantly Improved Survival Of Patients With High APACHE II Scores In ATHOS-3 Study

GIAPREZA™ (angiotensin II) Significantly Improved Survival Of Patients With High APACHE II Scores In ATHOS-3 Study

Analysis to Be Presented in Oral Session at the Society of Critical Care Medicine's 47th Critical Care Congress

First Week of LJPC February 16th Options Trading

First Week of LJPC February 16th Options Trading

Investors in La Jolla Pharmaceutical Co. saw new options become available this week, for the February 16th expiration.

Relative Strength Alert For La Jolla Pharmaceutical

Relative Strength Alert For La Jolla Pharmaceutical

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Notable Friday Option Activity: LJPC, BANC, SIEN

Notable Friday Option Activity: LJPC, BANC, SIEN

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in La Jolla Pharmaceutical Co. , where a total of 2,618 contracts have traded so far, representing approximately 261,800 underlying shares.

La Jolla Pharmaceutical Company Announces Financial Results For The Three And Nine Months Ended September 30, 2017 And Recent Corporate Progress

La Jolla Pharmaceutical Company Announces Financial Results For The Three And Nine Months Ended September 30, 2017 And Recent Corporate Progress

La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening...

Commit To Purchase La Jolla Pharmaceutical Co. At $25, Earn 14.7% Annualized Using Options

Commit To Purchase La Jolla Pharmaceutical Co. At $25, Earn 14.7% Annualized Using Options

Investors considering a purchase of La Jolla Pharmaceutical Co. stock, but tentative about paying the going market price of $34.75/share, might benefit from considering selling puts among the alternative strategies at their disposal.

La Jolla Pharmaceutical Company Announces Intent To Submit Marketing Authorization Application For LJPC-501 In The Third Quarter Of 2018

La Jolla Pharmaceutical Company Announces Intent To Submit Marketing Authorization Application For LJPC-501 In The Third Quarter Of 2018

La Jolla Pharmaceutical Company (NASDAQ:LJPC) (the Company or La Jolla) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued favorable Scientific...

Prespecified Analysis Of ATHOS-3 Indicates Survival Benefit In LJPC-501-Treated Patients With Relatively Low Angiotensin II State

Prespecified Analysis Of ATHOS-3 Indicates Survival Benefit In LJPC-501-Treated Patients With Relatively Low Angiotensin II State

La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla) today announced an abstract entitled "Baseline angiotensin levels and ACE effects in patients with vasodilatory shock treated with angiotensin...

La Jolla Pharmaceutical Company Announces U.S. FDA Acceptance Of New Drug Application For LJPC-501

La Jolla Pharmaceutical Company Announces U.S. FDA Acceptance Of New Drug Application For LJPC-501

La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla) today announced that the U.

La Jolla Pharmaceutical Company Announces Launch Of Expanded Access Program For LJPC-501

La Jolla Pharmaceutical Company Announces Launch Of Expanded Access Program For LJPC-501

La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), today announced that the Company has initiated an expanded access program (EAP) in the United States to provide its investigational drug,...

La Jolla Pharmaceutical Company Announces Financial Results For The Three And Six Months Ended June 30, 2017 And Recent Corporate Progress

La Jolla Pharmaceutical Company Announces Financial Results For The Three And Six Months Ended June 30, 2017 And Recent Corporate Progress

La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening...

Commit To Purchase La Jolla Pharmaceutical Co. At $24, Earn 17.3% Annualized Using Options

Commit To Purchase La Jolla Pharmaceutical Co. At $24, Earn 17.3% Annualized Using Options

Investors eyeing a purchase of La Jolla Pharmaceutical Co. shares, but tentative about paying the going market price of $31.41/share, might benefit from considering selling puts among the alternative strategies at their disposal.

Mixed Outcomes for La Jolla Pharma Shock Drug Fuels Debate Over Sales Potential

Mixed Outcomes for La Jolla Pharma Shock Drug Fuels Debate Over Sales Potential

LJPC-501 reversed dangerously low blood pressure in patients suffering from a severe form of shock, but the drug did not improve total organ function or reduce mortality.

Results Of ATHOS-3 Phase 3 Study Of LJPC-501 Published In The New England Journal Of Medicine

La Jolla Pharmaceutical Company (Nasdaq: LJPC) (La Jolla) today announced that results of the ATHOS-3 ( Angiotensin II for the Treatment of High- Output Shock) Phase 3 study of LJPC-501 (angiotensin II) have been...

6 Hot Unusual Volume Setups

6 Hot Unusual Volume Setups

Here's a technical look at how to play six stocks trending higher with unusual volume flows.

Short Interest Makes 11% Move For LJPC

The most recent short interest data has been released for the 04/28/2017 settlement date, which shows a 505,133 share increase in total short interest for La Jolla Pharmaceutical Co. , to 5,069,906, an increase of 11.07% since 04/13/2017.

La Jolla Pharmaceutical Enters Oversold Territory (LJPC)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.